TLR agonist treatment induced pro-inflammatory cytokines and NS3 pre-treatment does not induce immune tolerance. Ayilam Ramachandran Rajalakshmy Jambulingam Malathi Hajib Naraharirao Madhavan 10.1371/journal.pone.0125419.g010 https://plos.figshare.com/articles/figure/_TLR_agonist_treatment_induced_pro_inflammatory_cytokines_and_NS3_pre_treatment_does_not_induce_immune_tolerance_/1411843 <p>Microglia was exposed to 50 ng/ml of Pam2CSK4 and Pam3CSK4 and pro-inflammatory cytokine expressions were measured by ELISA. <b>(A and B)</b> Pam2CSK4 treatment induced IL-6 and TNF-α production at 3 and 16 hr time point. <b>(C and D)</b> Similarly Pam3CSK4 treatment induced IL-6 and TNF-α production. Microglial cells were pre-treated with 20 ng/ml of NS3 protein for 16 hrs before 6 hr NS3 treatment to study the immune tolerance induction by NS3. <b>(E)</b> There was no significant difference observed for TNF-α production inNS3 exposed and NS3 pre-treated cells. The data is expressed as mean (n = 3) ± SE, *p< 0.05.</p> 2015-05-12 02:50:40 NS 3 Tumor nicrosis factor HCV NS 3 protein Receptor Ligand Treatment Furnished Immune Tolerance BackgroundRecent evidence TLR agonists Pam 3CSK hepatitis C Virus NS 3 Mediated Microglial Inflammation ligands Pam 2CSK nf Hepatitis C virus elisa Nuclear Factor kappaB microglial cell line CHME 3.MethodsIL NS 3 protein cytokine gene expression cns tnf NS 3. TLR ligand treatment facs